Table 2. Baseline prognostic factors of PFS and OS in Chinese patients with mRCC treated with sorafenib.
| Characteristics | Median PFS (95% CI) (Months) | p value | Median OS (95% CI) (Months) | p value |
|---|---|---|---|---|
| Gender | ||||
| Male | 14.3 (9.7, 18.9) | 0.163 | 23.4 (14.0, 32.8) | 0.368 |
| Female | 11.1 (9.7, 12.4) | 22.2 (14.4, 30.1) | ||
| Age (Years) | ||||
| ≥58 | 23.3 (13.9, 32.7) | 0.020 | 33.8 (22.7, 44.9) | 0.082 |
| <58 | 10.9 (9.0, 12.8) | 20.4 (16.9, 24.0) | ||
| BMI (Mean ± SD) (kg/m2) | ||||
| ≥23.1 | 14.1 (11.2, 17.5) | 0.263 | 33.6 (22.0, 45.2) | 0.050 |
| <23.1 | 11.5 (6.7, 16.0) | 21.1 (18.1, 25.6) | ||
| MSKCC score | ||||
| Low risk | 42.1 (17.8, 66.3) | <0.001 | 97.2 (NA, NA) | <0.001 |
| Intermediate risk | 11.6 (8.6, 14.7) | 23.4 (20.2, 26.6) | ||
| High risk | 5.1 (3.4, 6.8) | 8.8 (6.9, 10.7) | ||
| ECOG performance status | ||||
| 0 | 25.7 (17.1, 34.3) | <0.001 | 44.9 (29.4, 60.4) | <0.001 |
| 1 | 11.5 (8.5, 14.5) | 20.7 (17.6, 23.7) | ||
| 2 | 5.9 (0.7, 11.1) | 10.8 (8.1, 13.5) | ||
| 3 | 3.4 (2.3, 4.4) | 8.8 (6.5, 11.0) | ||
| Histology | ||||
| Clear cell subtype | 16.3 (10.0, 22.6) | 0.001 | 28.7 (17.7, 37.7) | <0.001 |
| Non-clear cell subtypes | 6.9 (5.9, 8.2) | 11.3 (4.7, 17.8) | ||
| Tumor nucleus grade | ||||
| 1–2 | 35.0 (24.2, 45.8) | <0.001 | 52.4 (26.5, 78.2) | <0.001 |
| 3–4 | 10.8 (9.0, 12.7) | 19.4 (16.2, 22.6) | ||
| Previous nephrectomy | ||||
| Yes | 13.6 (7.8, 19.4) | 0.800 | 24.1 (15.5, 32.7) | 0.041 |
| No | 13.4 (10.0, 16.8) | 18.4 (11.5, 25.3) | ||
| Time from nephrectomy to sorafenib treatment | ||||
| Metastatic disease at diagnosis | ||||
| No palliative nephrectomy | 13.8 (7.9, 19.7) | <0.001 | 18.4 (10.3, 26.5) | <0.001 |
| Palliative nephrectomy | 11.3 (5.5, 17.0) | 23.4 (9.8, 36.9) | ||
| Metastatic disease after radical nephrectomy | ||||
| ≥12 months | 27.3 (15.2, 39.5) | 77.9 (30.1, 125.7) | ||
| <12 months | 7.1 (5.5, 8.7) | 16.8 (12.1, 21.5) | ||
| Metastatic organs | ||||
| 1 | 28.8 (20.8, 36.9) | <0.001 | 42.7 (27.1, 58.2) | <0.001 |
| 2 | 10.5 (7.5, 13.6) | 18.7 (15.7, 21.7) | ||
| 3 | 7.5 (3.3, 11.7) | 11.1 (7.0, 15.1) | ||
| 4 | 4.0 (2.9, 5.2) | 5.4 (3.4, 7.4) | ||
| Previous systemic therapy | ||||
| None | 14.1 (4.6, 23.5) | 0.109 | 24.9 (17.4, 32.4) | 0.246 |
| Cytokine | 13.6 (10.3, 16.8) | 22.4 (16.2, 28.7) | ||
| Sunitinib | 6.3 (3.5, 9.1) | 11.3 (9.6, 13.0) | ||
| Best response | ||||
| CR | 46.7 (NA, NA) | <0.001 | Not reached | <0.001 |
| PR | 25.0 (17.8, 32.2) | 42.7 (26.5, 59.7) | ||
| SD | 13.7 (10.1, 17.3) | 22.4 (19.3, 22.7) | ||
| PD | 2.1 (1.7, 2.5) | 6.7 (5.4, 7.9) |
BMI, body mass index; CR, complete remission; ECOG, Eastern Cooperative Oncology Group; MSKCC, Memorial Sloan-Kettering Cancer Center; NA, not applicable as was not achieved; OS, overall survival; PD, disease progression; PFS, progression-free survival; PR, partial remission; SD, stable disease.